Skip to content

Impairment Charges at other companies

TDS
Telephone and Data SystemsTDS
$900K-18.4%
Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
$6M
Corebridge Financial logo
Corebridge FinancialCRBG
$24M+20.0%
V.F. Corporation logo
V.F. CorporationVFC
$30.72M-39.8%
Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$0-100%
Lear Corporation logo
Lear CorporationLEA
$16.03M+510%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's impairment charges?
Indivior Pharmaceuticals, Inc. (INDV) reported impairment charges of $6M in Q1 2026.
What does impairment charges mean?
Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.